Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05280015
Other study ID # 2021/621
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 8, 2022
Est. completion date December 2024

Study information

Verified date September 2022
Source Centre Hospitalier Universitaire de Besancon
Contact Emmanuel HAFFEN, PhD
Phone 0033 3 81 21 90 07
Email emmanuel.haffen@univ-fcomte.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study aims to evaluate the contribution of a multi-targeted microbiotherapy at 12 weeks in depressed-patients in a situation of failure of a 1st line of antidepressant treatment and treated in add-on with a 2nd antidepressant, venlafaxine.


Description:

Depression is the most common psychiatric illness and has major personal, societal and economic consequences. Increase in the disease prevalence is significantly associated with certain somatic pathologies, including metabolic diseases and functional intestinal disorders. From a therapeutic point of view, approximately 2/3 patients are not in remission after first-line antidepressant treatment. Moreover, 20 to 30% patients resist at all the therapeutic strategies classically proposed in this indication. The identification of new therapeutic strategies is therefore a major challenge, especially for patients with chronic depression resistant to standard treatments. Various research studies have shown the involvement of inflammatory mechanisms in depression. Thus, the increase in the disease prevalence is significantly associated with certain somatic pathologies, in particular metabolic diseases, a certain number of which are linked to abnormalities of the intestinal microbiota. In this context, the use of probiotics is interesting because some have antidepressant effects, anti-inflammatory and metabolic properties. However, even if a few studies have shown an antidepressant effect of probiotics with improvement of biological markers of inflammation, it seems that the use of probiotics alone is not sufficient for lasting results on depressive symptoms. The PROMOOD clinical research project fits into this context. We propose to carry out a multicenter clinical study with the product developed by GYNOV (GynMDD® multitarget compound with 3 active ingredients: an amino acid (L-glutamine), an ingredient purified from a plant extract (Cavacurmine) and a probiotic (Lactobacillus rhamnosus GG). In a preclinical study carried out at the CNRS on 144 mice, a synergy of action between these 3 ingredients was demonstrated on the anxio-depressive systems, resulting in an improvement far greater than the expected effect of composition and comparable to a reference injectable antidepressant (clomipramine). In theses context, the microbiotherapy proposed in this project is very original because: - a multi-target approach targeting several mechanisms of action: intestinal permeability, glutamine/glutamate/GABA cycle, insulin resistance, immunomodulation, oxidative stress; - prospect of an optimization/simplification of care; - It is very acceptable for patients both from the point of view of tolerance and from the economic point of view. With a phase II, prospective, multicenter design, this study aims to evaluate the contribution and the tolerance of a multi-targeted microbiotherapy in addition to venlafaxine, in a second-line antidepressant treatment. The treatment will be delivered during 12 weeks. Baseline measures will be compared to those obtained during the treatement administration (every week) and after the treatment administration (every week for the next 12 weeks).


Recruitment information / eligibility

Status Recruiting
Enrollment 92
Est. completion date December 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis of unipolar MDD (Diagnostic and Statistical Manual of Mental Disorders V [DSM-V], QIDS-C16=15) - No response at a first antidepressant - under venlafaxine - Signed informed consent form - Subjects affiliated to or beneficiary from a French social security regime Exclusion Criteria: - Contraindications to probiotic administration - Allergy to one of the compounds of the multi-target probiotic or the placebo - consuming probiotic-based dietary supplements - Patient with other psychiatric disorders, except social anxiety disorder, generalized anxiety disorder and nicotine use disorder - Patient with a serious and/or progressive medical condition, including chronic inflammatory pathologies or autoimmune diseases requiring long-term anti-inflammatory treatment (including corticosteroid therapy) or immunosuppressant. - Patient with a recent infectious episode likely to require antibiotic therapy. - Patient presenting with a suicidal risk assessed by the suicide item of the QIDS-C16 scale (score item 12 of the QIDS-C16 >2) - Other concomitant antidepressant and/or lithium and/or anti-inflammatory treatment for the duration of the study - Subject under measure of protection or guardianship of justice - Subject beneficiary from a legal protection regime - Subject unlikely to cooperate or low cooperation stated by investigator - Subject not covered by social security - Pregnant woman - Subject being in the exclusion period of another study or provided for by the "National Volunteer File

Study Design


Intervention

Dietary Supplement:
microbiotherapy (GynMDD)
multi-target microbiotherapy add-on venlafaxine
Other:
placebo
placebo add-on venlafaxine

Locations

Country Name City State
France Emmanuel HAFFEN Besançon
France Centre Hospitalier Spécialisé Charles Perrens Bordeaux
France CHU de Clermont-Ferrand Clermont-Ferrand
France Hôpital Henri Mondor / APHP Créteil

Sponsors (3)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon Fondation FondaMental, GYNOV

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Quick Inventory of Depressive Symptomatology (QIDS-C16) at 12 weeks The QIDS-C16 is a 16-item scale that is clinician-rated; it is designed to assess the severity of depressive symptoms. The QIDS-C16 total score ranges from 0-27. Scores ranging from 0 to 10 correspond with no to mild depression, while scores >/= 11 correspond to moderate to severe depression. A negative change indicates improvement in the subject's depression, and a positive change indicates a worsening of the subject's depression. baseline (Day 0), Week 12 (W12) post-treatment
Secondary Change from Severity of depressive symptoms evaluated by the clinician The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression. baseline (Day 0), at the end of therapy (week 12 (W12)
Secondary Change from Severity of depressive symptoms evaluated by the patient Score achieved on the validated self-reported (QIDS-SR16) evaluating the severity of depressive symptoms. QIDS-SR-16 is a standard questionnaire "The Quick Inventory of Depressive Symptomatology" (16-Item) (Self-Report). This covers questions on falling asleep, sleep during the night, waking up , sleeping too much, feeling sad ,appetite, weight, concentration , how they view themselves, thoughts of death and suicide, general interests, energy levels, feeling slowed down , feeling restless. baseline (Day 0), at the end of therapy (week 12 (W12)
Secondary Evaluation of treatment observance A treament observance book was complied by patient during the 12 weeks of therapy baseline (Day 0), at the end of therapy (week 12 (W12)
Secondary Change from Health related Quality of Life (HrQoL) HrQOL will be assessed using health status measures of the EuroQuality of Life Five Dimensions (EQ-5D-5L) baseline (Day 0), at the end of therapy (week 12 (W12)
Secondary Change from anxiety anxiety assessed using Brief Anxiety Scale of Tyrer (BAS) baseline (Day 0), at the end ot therapy (week 12 (W12)
Secondary Change from digestive health digestive evaluation assessed by digestive health scale, scale developped by gastroenterlogists (https://www.worldgastroenterology.org/search?cx=005474681532606414716%3AWMX-367025812&cof=FORID%3A9&ie=UTF-8&q=digestive+health+evaluation) baseline (Day 0), at the end ot therapy (week 12 (W12)
Secondary Change from serum Inflammatory biological markers inflammatory inflammatory levels (CRP, Il-1b, Il-6 and TNF-a) in blood samples baseline (Day 0), at the end ot therapy (week 12 (W12)
Secondary Change from Biological markers of intestinal dysbiosis zonulin and serobank levels in blood samples baseline (Day 0), at the end ot therapy (week 12 (W12)
Secondary Change from Metagenomic shotgun sequencing of gut microbiota preforming metagenomic shotgun sequencing of fecal DNA to determine the changes in the intestinal microbiota composition, diversity and functionality baseline (Day 0), at the end ot therapy (week 12 (W12)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A